The Challenge
After targeted inhibitor resistance, faced multiple antibody-drug conjugate trials with unclear differences.
Our Impact
Cancer Commons compared mechanisms, efficacy data, and development stages of competing trials, enabling informed selection of a phase 3 trial at a top cancer center.
The Outcome
She experienced significant tumor reduction with good tolerability to the clinical trial treatment—confirmation of optimal trial enrollment based on scientific evidence and rationale.
